44

SARS-CoV-2 antibodies remain detectable 12 months after infection and antibody 2 magnitude is associated with age and COVID-19 severity 3 4 Eric D. Laing, PhD<sup>1†</sup>, Nusrat J. Epsi, PhD<sup>2,3†</sup>, Stephanie A. Richard, PhD<sup>2,3</sup>, Emily C. Samuels, BS<sup>1,3</sup>, Wei Wang, PhD<sup>4</sup>, Russell Vassell, MS<sup>4</sup>, Daniel F. Ewing, PhD<sup>5</sup>, Rachel Herrup<sup>4</sup>, Spencer 5 L. Sterling, MpH<sup>1,3</sup>, David A Lindholm, MD<sup>6</sup>, Eugene V. Millar, PhD<sup>2,3</sup>, Ryan C. Maves, MD<sup>7</sup>, Derek T. Larson, DO<sup>8</sup>, Rhonda E. Colombo, MD<sup>2,3,9</sup>, Sharon Chi, DO<sup>10</sup>, Cristian Madar, MD<sup>10</sup>, 6 7 Tahaniyat Lalani, MBBS<sup>11</sup>, Anuradha Ganesan, MBBS<sup>2,3,12</sup>, Anthony Fries, PhD<sup>13</sup>, Christopher J. 8 Colombo, MD<sup>9</sup>, Katrin Mende, PhD<sup>2,3,6</sup>, Mark P. Simons, PhD<sup>1,2</sup>, Kevin L. Schully, PhD<sup>5</sup>, Carol 9 D. Weiss, PhD<sup>4</sup>, David R. Tribble, MD<sup>2</sup>, Brian K. Agan. MD<sup>2,3</sup>, Simon D. Pollett, MBBS<sup>2,3</sup>, Christopher C. Broder, PhD<sup>1</sup>, and Timothy H. Burgess, MD\*<sup>2</sup> for the EPICC Study Team 10 11 12 13 <sup>1</sup>Department of Microbiology and Immunology, Uniformed Services University of the Health 14 Sciences, Bethesda, MD, USA <sup>2</sup>Infectious Disease Clinical Research Program, Department of Preventive Medicine and 15 16 Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, USA 17 <sup>3</sup>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD 18 <sup>4</sup>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, 19 20 MD, USA 21 <sup>5</sup>Biological Defense Research Directorate, Naval Medical Research Center-Fort Detrick, 22 Frederick, MD, USA 23 <sup>6</sup>Brooke Army Medical Center, Fort Sam Houston, TX, USA 24 <sup>7</sup>Naval Medical Center San Diego, San Diego, CA, USA 25 <sup>8</sup>Fort Belvoir Community Hospital, Fort Belvoir, VA, USA 26 <sup>9</sup>Madigan Army Medical Center, Joint Base Lewis-McChord, WA 27 <sup>10</sup>Tripler Army Medical Center, Honolulu, HI, USA 28 <sup>11</sup>Naval Medical Center Portsmouth, Portsmouth, VA, USA 29 <sup>12</sup>Walter Reed National Military Medical Center, Bethesda, MD 30 <sup>13</sup>U.S. Air Force School of Aerospace Medicine, Dayton, Ohio, USA 31 32 <sup>†</sup>Denotes equal contribution 33 34 \*Correspondence 35 T. H. Burgess, MD, MPH, FACP 36 Captain, Medical Corps, U.S. Navv 37 Director, Infectious Diseases Clinical Research Program 38 Associate Professor, Department of Preventive Medicine and Biostatistics 39 Uniformed Services University (USU) 40 office +1 301-295-1579 mobile +1 301-221-0399 41 email timothy.burgess@usuhs.edu 42 43

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

**ABSTRACT** Importance: The persistence of SARS-CoV-2 antibodies may be a predictive correlate of protection for both natural infections and vaccinations. Identifying predictors of robust antibody responses is important to evaluate the risk of re-infection / vaccine failure and may be translatable to vaccine effectiveness. Objective: To 1) determine the durability of anti-SARS-CoV-2 IgG and neutralizing antibodies in subjects who experienced mild and moderate to severe COVID-19, and 2) to evaluate the correlation of age and IgG responses to both endemic human seasonal coronaviruses (HCoVs) and SARS-CoV-2 according to infection outcome. Design: Longitudinal serum samples were collected from PCR-confirmed SARS-CoV-2 positive participants (U.S. active duty service members, dependents and military retirees, including a range of ages and demographics) who sought medical treatment at seven U.S. military hospitals from March 2020 to March 2021 and enrolled in a prospective observational cohort study. Results: We observed SARS-CoV-2 seropositivity in 100% of inpatients followed for six months (58/58) to one year (8/8), while we observed seroreversion in 5% (9/192) of outpatients six to ten months after symptom onset, and 18% (2/11) of outpatients followed for one year. Both outpatient and inpatient anti-SARS-CoV-2 binding-IgG responses had a half-life ( $T_{1/2}$ ) of >1000 days post-symptom onset. The magnitude of neutralizing antibodies (geometric mean titer, inpatients: 378 [246-580, 95% CI] versus outpatients: 83 [59-116, 95% CI]) and durability (inpatients: 65 [43-98, 95% CI] versus outpatients: 33 [26-40, 95% CI]) were associated with COVID-19 severity. Older age was a positive correlate with both higher IgG binding and neutralizing antibody levels when controlling for COVID-19 hospitalization status. We found no significant relationships between HCoV antibody responses and COVID-19 clinical outcomes, or the development of SARS-CoV-2 neutralizing antibodies. Conclusions and Relevance: This study demonstrates that humoral responses to SARS-CoV-2 infection are robust on longer time-scales, including those arising from milder infections.

However, the magnitude and durability of the antibody response after natural infection was lower and more variable in younger participants who did not require hospitalization for COVID-19. These findings support vaccination against SARS-CoV-2 in all suitable populations including those individuals that have recovered from natural infection.

#### INTRODUCTION

The immune correlates of protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) are unknown. However, the development of detectable humoral immunity is likely a predictive surrogate of protection<sup>1,2</sup>. The presence of broadly neutralizing serum antibodies five to eight months after SARS-CoV-2 infection have been documented by several groups<sup>3-10</sup>. Cases of symptomatic COVID-19 following re-infection with SARS-CoV-2 have been reported but are infrequent<sup>11-15</sup>, and recent studies have highlighted a correlation between the presence of SARS-CoV-2 antibodies and decreased risk of reinfections<sup>16,17</sup>.

The magnitude of the antibody response to SARS-CoV-2 infection has been positively correlated with COVID-19 severity<sup>18-25</sup>, but the confounding effect of age on this association remains unresolved<sup>26-28</sup>. Even less understood is whether cross-reactive seasonal human coronavirus (HCoV) antibodies correlate with the kinetics of SARS-CoV-2 humoral responses across acute and post-acute timescales after SARS-CoV-2 infection<sup>29-32</sup>. Pre-existing HCoV antibodies that cross-react with but do not cross-neutralize SARS-CoV-2 have been detected<sup>30,33-36</sup>, and recent infection with HCoVs has been correlated with reduced COVID-19 severity<sup>37</sup>.

Here, we demonstrate the persistence of SARS-CoV-2 IgG binding and neutralizing responses out to twelve months in participants enrolled in a prospective study at seven military treatment facilities (MTFs) across the U.S. from March 2020 to March 2021. MTFs provide care for active duty servicemembers, dependents and military retirees, including a range of ages and

demographics that is broadly representative of the civilian U.S. population. Study participants were followed for up to twelve months allowing analyses to identify correlates of long humoral immune durability to SARS-CoV-2. The aims are to (i) describe the magnitude and durability of SARS-CoV-2 antibody response for one year after natural infection, and (ii) identify correlates of SARS-CoV-2 antibody response, including COVID-19 severity, age, and antibody profiles to HCoVs.

#### **METHODS**

Study population, setting, participant enrollment and sera collection

Participants were enrolled and serum samples were collected in the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (EPICC) protocol: a prospective, longitudinal study of COVID-19. The protocol was approved by the Uniformed Services University Institutional Review Board (IDCRP-085), and all subjects or their legally authorized representative provided informed consent to participate. Participants were enrolled at seven MTFs across the United States, including Walter Reed National Military Medical Center (Bethesda, MD), Brooke Army Medical Center (San Antonio, TX), Naval Medical Center San Diego (San Diego, CA), Naval Medical Center Portsmouth (Portsmouth, VA), Madigan Army Medical Center (Tacoma, WA), Fort Belvoir Community Hospital (Fort Belvoir, VA) and Tripler Army Medical Center (Honolulu, HI). Eligible participants included individuals with laboratory-confirmed SARS-CoV-2 infection by nucleic acid amplification test (NAAT), individuals with SARS-CoV-2-like illness, and individuals who were tested following a high risk exposure to a SARS-CoV-2 positive person or screening surrounding travel. Blood specimens were collected at enrollment, and then at seven, fourteen, and twenty-eight days, and subsequently at three, six and twelve months after enrollment.

Antibody results from SARS-CoV-2 PCR-positive (n=505) and SARS-CoV-2 PCR-negative (n=92) participants were included in the evaluation of humoral response to SARS-CoV-

2 infection. From these participants, we analyzed spike protein IgG binding in a serial collection of 764 serum samples from 250 (outpatients n= 192, inpatients n= 58) participants who were followed through six and twelve months-post-enrollment. Six months serum samples from these participants were collected at a median 188 days post-symptom onset (dpso), IQR= 15. Of these 250 participants, 19 (outpatients, n= 11; inpatients= 8) had available sera drawn twelve months from the onset of symptoms and prior to vaccination, allowing long-term monitoring of IgG duration (eFigure 1). Serum samples collected from individuals after the administration of COVID-19 vaccinations were excluded from this analysis of antibody responses to natural infection. To characterize the durability of the neutralizing antibody response to SARS-CoV-2, paired sera from 72 participants who had serum samples collected during early convalescence (median 36 dpso, IQR= 14.50) and at six months-post symptom onset collected from September to October 2020 were evaluated by a SARS-CoV-2 S-pseudovirus neutralization test (SNT) and an authentic wild-type SARS-CoV-2 virus neutralization test (VNT). Twelve months-post sera collected in March 2021 from 7 inpatients and 4 outpatients were further evaluated by SNT.

#### Multiplex microsphere-based immunoassay screening procedures

Detailed experimental procedures of SARS-CoV-2 and HCoV spike protein-based multiplex microsphere immunoassays have been previously described<sup>38-40</sup> and are described further in the Supplementary Appendix (eMethods). Briefly, diluted serum and capillary blood samples were tested in technical duplicates. Antigen-antibody complexes were analyzed on Bio-Plex 200 multiplexing systems (Bio-Rad, Hercules, CA) for IgG binding and median fluorescence intensity (MFI) values are reported.

SARS-CoV-2 S-pseudovirus production and neutralization (SNT)

The spike (S) sequence from SARS-CoV-2 isolate Wuhan-Hu-1 (GenBank accession: YP\_009724390.1) was used to construct lentiviral pseudoviruses for the neutralization assays, as described previously<sup>41</sup>. Additional details are provided in the (eMethods), briefly, pseudovirus titers were measured by infecting 293T-ACE2.TMPRSS2 cells. Pseudovirus titers were determined as relative luminescence units per milliliter of pseudovirus supernatants (RLU/ml). The antibody dilution causing a 50% and 80% reduction (inhibitory concentration, IC) of vector-expressed luciferase compared to control (IC<sub>50</sub>- and IC<sub>80</sub>-neutralizing antibody titer, respectively) was calculated with nonlinear regression using GraphPad Prism. Data reported were averages from at least two independent experiments.

#### Wild-type SARS-CoV-2 plaque reduction neutralization tests (VNT)

VNT antibody titers were determined by plaque reduction neutralization test (PRNT) as previously described with modifications<sup>42</sup>. Details of experimental procedures are included in the Supplementary Appendix (eMethods). SARS-CoV-2 (USA WA1/2020, BEI Resources cat # NR-52281) and serum samples were incubated for one hour then incubated with Vero-81 cells (ATCC cat NoCRL-1587). Cutoffs for 80% PRNT titers (PRNT<sub>80</sub>) were determined on each plate. Wells with an OD<sub>405</sub> less than 20% of the mean value of nine virus only controls, plus one standard deviation, were considered neutralizing.

#### Statistical analysis of humoral response correlates

Log-scale transformations were applied to all SARS-CoV-2 IgG binding and neutralization antibody datasets to explore normality and parametric or non-parametric were applied as indicated. For VNT PRNT80 titers, zero values were changed to 0.01 prior to log10-transformation and nonparametric unpaired Mann-Whitney tests were performed. Generally, second order polynomial curves were the preferred non-linear regression model ( $\alpha$ = 0.05) and these best-fit curves with confidence intervals are shown in all graphs. Exponential phase-decay

analyses were used to explore antibody half-life  $(T_{1/2})$  trends utilizing subjects with  $\geq 2$  longitudinal sera samples, and, based on best-fit, either a one-phase or two-phase decay model was preferred. When single models for all the datasets were not preferred or a best-fit single curve was ambiguous, a robust fit without curve fitting was applied and the mean of all subjects' individual  $T_{1/2}$  was calculated; in several instances  $T_{1/2}$  exceeded 1000 days and were reported as >1000. We used Brown-Forsythe and Welch's ANOVA to compare age-stratified log10-transformed IgG binding MFI data and adjusted for multiple comparisons through use of the Dunnet's multiple T3 comparison test. Box-Cox transformations were applied to HCoV IgG binding MFI values to normalize the data and parametric t-tests were performed. Multivariate linear regression models were used to compare MFI among age groups and by hospitalization status (with interaction term), and separate models were run for samples collected in the early convalescence period and at six months-post. Figures were generated and statistical analyses were performed in GraphPad Prism version 9.0.2 and RStudio version 4.0.2 software (R Foundation for Statistical Computing)<sup>43</sup>.

#### **RESULTS**

Demographic and hospitalization status of EPICC participants

Over half of the participants were 18-44 years of age or male. The racial distribution of participants was non-Hispanic white (44.3%), followed by Hispanic (31.2%) and African-American (14.1%) (Table 1). Participants were classified according to the maximum severity reported during follow-up as hospitalized (inpatients) or outpatients. Participants were stratified into three age groups: 18-44, >44-64 and  $\geq$ 65 years old. The median age of inpatient and outpatient participants was 58.2 (interquartile range (IQR)= 16.3 years) and 43.3 (IQR= 24.4) years, respectively.

SARS-CoV-2 binding and neutralizing antibody responses differ by COVID-19 severity

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

We observed 95% (183/192) of outpatients and 100% of inpatients (58/58) remained seropositive at six months-post, and 9/11 outpatients and 8/8 inpatients remained seropositive at 12 months-post symptom onset. A one-phase decay of the IgG response of inpatients calculated a  $T_{1/2}$  >1000 days (Figure 1A). IgG responses displayed greater heterogeneity among outpatients than inpatients and a one-phase decay curve modeled a  $T_{1/2}$ = 1232 days (Figure 1A). Next, we sought to investigate whether the magnitude or duration of the IgG response was associated with COVID-19 clinical disease severity as determined by hospitalization status. For this analysis, magnitude was explored as IgG responses recorded during early convalescence for each participant across all longitudinal sera collections and the durability of the antibody response was assessed with sera collected six and twelve monthspost symptom onset. Geometric mean IgG levels during early convalescence and six monthspost-infection were significantly higher in inpatients than in outpatients (early convalescence: inpatients= 27,646 MFI [95% Confidence Interval (CI): 26,688-28,639], outpatients= 20,587 MFI [CI:19,057-22,241], P <0.001; six months-post-infection: inpatients= 22,694 MFI [95% CI: 19,967-25,792], outpatients= 13,559 MFI [95% CI: 12,343-14,895], P < 0.001) (Figure 1B). By twelve months-post we found no differences in geometric mean IgG binding between inpatients (14,755 [95% CI: 11,181-19,472]) and outpatients (10,588 [95% CI: 6,421-17,460]) (P= 0.78). In addition to MFI as a measurement of IgG binding, we determined anti-SARS-CoV-2 IgG endpoint titers. Again, we found that the geometric mean of endpoint titers (GMT) were significantly higher for inpatients than outpatients during early convalescence (inpatients= 13,029 [95% CI: 9375-18,108], outpatients= 3240 [95% CI: 2323-4518]) (eFigure 2A), and six months-post (inpatients= 8268 [95% CI: 5323-12,843], outpatients= 2216 [95% CI: 1654-2970]) (eFigure 2B). Next, sera were assessed for neutralizing antibodies by SNT; IC<sub>80</sub> titers are shown in

Figures 1 and 2, while IC<sub>50</sub> titers are provided in eFigure 3A-C. A one-phase decay modeled

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

inpatient  $T_{1/2}$  neutralizing antibody responses of 88 days and a two-phase decay of outpatient neutralizing antibody responses calculated a mean fast/slow- $T_{1/2}$  of 77/132 days (Figure 1C). The neutralizing antibody GMT was greater for inpatients than outpatients during both early convalescence, 378 [95% CI: 246-580] versus 83 [95% CI: 59-116] (P < 0.001), and six monthspost, 65 [95% CI: 43-98] versus 33 [95% CI: 26-40] (P= 0.006), although these differences were not observed by twelve months-post (Figure 1D). These significant associations between COVID-19 severity, and IC<sub>80</sub> neutralizing antibody kinetics and durability were also observed with  $IC_{50}$  titers (eFigure 3A-C). Recapitulating the durability, magnitude, and correlates of humoral immune response to SARS-CoV-2 across different populations with different neutralization assays remains a critical goal<sup>44</sup>. Antibody neutralization was further characterized by a wild-type SARS-CoV-2 VNT. Endpoint titers in VNT correlated significantly and had a modest coefficient strength with SNT titers (Spearman's  $\rho = 0.77$ , P < 0.001) (eFigure 4A). A one-phase decay of VNT neutralizing antibody responses calculated a  $T_{1/2}$  of 106 and 29 days for inpatients and outpatients, respectively (eFigure 4B-C). The magnitude and durability of VNT GMT was also different between inpatients and outpatients during early convalescence (inpatients=52 [95% CI: 14-198], outpatients=11 [95% CI: 4-29], P < 0.001) and six months-post (inpatients=14 [95% CI: 3-71], outpatients=2 [95% CI: 0.5-5], P= 0.02) (eFigure 4D). Age correlation with antibody durability may be explained by age-specific clinical severity Because age is associated with hospitalization status, we used a multivariate regression model to explore antibody magnitude and durability on the basis of COVID-19 severity and age (groups: 18-44, >44-64, and ≥65-years-old). This analysis revealed that during early convalescence IgG levels were higher for all inpatient participants, and increased with age for outpatients with significantly higher IgG-binding levels in ≥65-years-old outpatients that was comparable to ≥65-years-old inpatients (Figure 2A). Furthermore, significant differences in IgG-

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

binding levels were noted between outpatients in 18-44-years-old (19,124 MFI [95% CI: 17,058-21,439, P < 0.001) and >44-64-years-old groups (20,897 MFI [95% CI: 18,404-23,728], P <0.001) compared to the ≥65-years-old group (27,703 MFI [95% CI: 26,401-29,069]) (Figure 2B). By six months-post, IgG levels remained higher for inpatients across age groups than the outpatients (Figure 2C), and significantly so for the >44-64-years-old (24,789 MFI [95% CI: 22,947-26,779], P=0.019) compared to the 18-44 years-old age group (Figure 2D). Additionally, no differences in the IgG response were detected by twelve months-post (eFigure 5A). The IgG  $T_{1/2}$  of outpatient age groups 18-44-year-old. >44-64-year-old and  $\geq$ 65-year-old, were >1000. 230, and 143 days, respectively (eFigure 5B). Compared to age-grouped outpatients, IgG  $T_{1/2}$  of inpatient age groups were slower, >1000 days for all 18-44-year-old, >44-64-year-old and ≥65year-old age groups (eFigure 5C). Next, we compared age-stratified neutralizing antibody titers across outpatients and inpatients. In outpatient 18-44, >44-64 and ≥65 age-groups, neutralizing antibodies one-phase decay  $T_{1/2}$  were 16, 34, and 21 days, respectively (Figure 3A). Strikingly, we noted a higher magnitude during early convalescence in outpatients ≥65-years-old (GMT: 233 [95% CI: 111-489]) compared to 18-44 (GMT: 67 [95% CI: 37-120], P= 0.052) and >44-64 (GMT: 80 [95% CI: 50-127], (P= 0.037) years-old groups (Figure 3B). However, this difference was not observed by six months-post, correlating with the short  $T_{1/2}$  in the  $\geq$ 65-years-old group (Figure 3B). The slowest one-phase decay  $T_{1/2}$  was observed in the inpatient  $\geq$ 65-years-old group, 84 days (Figure 3C), and when comparing inpatient neutralizing antibodies during early convalescence. higher GMT were observed in the >44-64 and ≥65-years-old groups, 505 [95% CI: 346-738] (P= 0.14) and 328 [95% CI: 187-576] (P= 0.18), respectively (Figure 3D). These results appear to suggest that the correlation between age and early humoral response is confounded by agespecific severity of SARS-CoV-2 infection, consistent with other findings<sup>45</sup>.

Seasonal HCoV antibody responses are not correlated with COVID-19 outcomes or the development of neutralizing antibodies

We first explored whether subjects with PCR-confirmed SARS-CoV-2 infection possessed higher levels of HCoV spike protein reactive antibodies as compared to SARS-CoV-2 negative subjects. Higher levels of HCoV-OC43 and HCoV-HKU1 reactive IgG, but not of HCoV-229E and HCoV-NL63 were observed in SARS-CoV-2-positive subjects during early convalescence across age groups with mild to severe COVID-19 (Figure 4A). Further, we identified a positive correlation and distinct clustering of maximum IgG levels between SARS-CoV-2 and seasonal betacoronaviruses (HCoV-OC43 and HCoV-HKU1) that was related to dpso (eFigure 6A-B), but only very weak relationships with the seasonal alphacoronaviruses (HCoV-229E and HCoV-NL63) (eFigure 6C-D). To examine the clinical correlation between HCoV antibody responses and COVID-19 severity, subjects were again stratified by age and clinical phenotype; we observed no significant correlation with HCoV peak antibody responses (Figure 4B). Finally, we sought to determine whether the induction of cross-reactive HCoV antibodies following SARS-CoV-2 infection were associated with the magnitude or durability of neutralizing antibodies to SARS-CoV-2. The magnitude of HCoV-OC43 and HCoV-HKU1 IgG titers during early convalescence was not significantly associated with SARS-CoV-2 neutralizing antibody responses during either early convalescence or six months-post symptom onset (eFigure 7A-D).

#### **DISCUSSION**

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

In this study, we have demonstrated that SARS-CoV-2 binding IgG and neutralizing antibodies remained detectable for up to one year in subjects following mild and moderate to severe COVID-19. Further, we corroborated that the magnitude and durability of humoral immune response are positively correlated, reflected by both  $T_{1/2}$  and levels of binding IgG and neutralizing antibody detected at time periods during early convalescence and six months-post

symptom onset <sup>46,47</sup>. This may be due to robust stimulation of humoral immunity with failure to control infection via innate responses.

Notably, when we controlled for hospitalization status, older age was positively correlated with robust positive antibodies and neutralizing antibody responses. This suggests a lack of immunosenescence driving waning humoral responses or seroreversion as all instances of seroreversion between six to twelve months-post symptom onset occurred in outpatient participants <65 years old (median age 30, Q1=26, Q3=43). Although, the association between age and disease severity may confound this observation. The interaction between age, severity and adaptive responses is complex<sup>48,49</sup>; we noted that age ≥65 years was significantly associated with the magnitude and durability of IgG responses for outpatients, whereas no differences were found for inpatients across the age groups. However, sample size was smaller in the inpatient group so this observation needs to be investigated further. Additionally, the magnitude of the early neutralizing antibody response increased incrementally in outpatients and inpatients age groups >44 years old. Interestingly, no significant differences in neutralizing antibody levels were observed across age groups by six months after symptom onset.

When we assessed HCoV seroresponses in our cohort, we found no association with the presence of antibodies to seasonal HCoVs and COVID-19 severity or with the development of SARS-CoV-2 neutralizing antibodies. The induction of antibodies cross-reactive with HCoV spike proteins after SARS-CoV-2 infection and boosted HCoV-HKU1 and HCoV-OC43 responses were observed, implying that highly conserved betacoronavirus spike protein epitopes, possibly conformation-dependent, are cross-reactive<sup>50</sup>. This conclusion is supported by prior observations that conserved regions of the SARS-CoV-2 spike protein S2 subunit have been shown to stimulate specific memory B cell repertoires<sup>51,52</sup>. Although this investigation is limited by the lack of baseline pre-SARS-CoV-2 infection sera, we also showed that boosted HCoV-OC43 and HCoV-HKU1 memory responses were not associated with COVID-19 clinical outcomes nor detrimental to the *de novo* development of SARS-CoV-2 neutralizing antibodies<sup>30</sup>.

Our finding of variable waning yet persistent neutralization titers across participants groups is consistent with other longitudinal studies<sup>7,53-55</sup>, however neutralization presents only one facet of long term SARS-CoV-2 immunity. Memory B cells specific to the SARS-CoV-2 spike receptor-binding domain, which are immunodominant and responsible for 90% of neutralizing activity<sup>56</sup>, have been detected even when circulating serum neutralizing antibodies have waned below detectable limits<sup>7,55</sup>.

Our results add to the growing body of literature that suggests humoral immunity following natural infection with SARS-CoV-2 is long lived, including out to one year post-infection. However, the magnitude and durability of SARS-CoV-2 antibody response was lower and more variable in younger participants (<65 years old) who experienced less severe COVID-19 and did not require hospitalization. These findings suggest that implementation of vaccination against SARS-CoV-2 infection in all suitable populations, including those individuals that have recovered from natural infection, would be prudent because vaccine induced immunity to SARS-CoV-2 will likely be more long-lived than that elicited from mild COVID-19. Additional studies will also be critical to further examine the protective role and durability of antibody responses following SARS-CoV-2 re-infection and/or vaccination up to and beyond one year.

#### **DECLARATIONS**

This research protocol, IDCRP-085, was approved by the Uniformed Services University Institutional Review Board.

#### STATEMENT OF ETHICS

The referenced human subjects protocol (IDCRP-085) was approved by the Uniformed Services University Institutional Review Board and participating sites. All subjects or their legally authorized representative provide written or verbal informed consent using approved documents

and procedures; the consent forms include clauses allowing use of specimens for investigations including those conducted in this study.

## **CONFLICT OF INTEREST**

None of the authors have any conflicts of interest of relevance to disclose.

## **DISCLAIMER**

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

The contents of this publication are the sole responsibility of the author(s) and do not necessarily reflect the views, opinions, or policies of the Uniformed Services University (USU), the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF), National Institutes of Health or the Department of Health and Human Services, Brooke Army Medical Center, Naval Medical Center Portsmouth, Tripler Army Medical Center, Naval Medical Center San Diego, Madigan Army Medical Center, Walter Reed National Military Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the US Department of Defense (DoD), the Departments of the Air Force, Army or Navy, or the U.S. Government. Mention of trade names, commercial products, or organization does not imply endorsement by the U.S. Government. The investigators have adhered to the policies for protection of human subjects as prescribed in 45 CFR 46. A number of the co-authors are employees of the U.S. Government or military service members. This work was prepared as part of their official duties. Title 17 U.S.C. §105 provides that 'Copyright protection under this title is not available for any work of the United States Government.' Title 17 U.S.C. §101 defines a U.S. Government work as a work prepared by a military service member or employee of the U.S. Government as part of that person's official duties.

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

**FUNDING** This project has been funded by the Defense Health Program, U.S. DoD, under awards HU0001190002 and HU00012020067, and the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under award HU00011920111 and Inter-Agency Agreement Y1-AI-5072. **ACKNOWLEDGEMENTS** We thank Dominic Esposito. Matthew Drew, Jennifer Melhako, Kelly Snead, Vanessa Wall. John-Paul Denson, Simon Messing, and William Gillette (Protein Expression Lab, FNCLR) for provision of HCoV-HKU1 and HCoV-OC43 spike proteins and excellent technical assistance. Additionally, we thank Shreshta Phogat (USU, HJF) for technical assistance. We also thank the members of the EPICC COVID-19 Cohort Study Group for their many contributions in conducting the study and ensuring effective protocol operations. The following members were all closely involved with the design, implementation, and oversight of the study. Brooke Army Medical Center, Fort Sam Houston, TX: J. Cowden; D. Lindholm; A. Markelz; K. Mende; T. Merritt; R. Walter; CPT T. Wellington Carl R. Darnall Army Medical Center, Fort Hood, TX: MAJ S. Bazan Fort Belvoir Community Hospital, Fort Belvoir, VA: L. Brandon; N. Dimascio-Johnson; MAJ E. Ewers; LCDR K. Gallagher; LCDR D. Larson; MAJ M. Odom Henry M. Jackson Foundation, Inc., Bethesda, MD: P. Blair; D. Clark Madigan Army Medical Center, Joint Base Lewis McChord, WA: LTC C. Colombo; R. Colombo; CPT C. Conlon; CPT K. Everson; LTC P. Faestel; COL T. Ferguson; MAJ L. Gordon; LTC S. Grogan; CPT S. Lis; COL C. Mount; LTC D. Musfeldt; MAJ R. Sainato; C. Schofield; COL C. Skinner; M. Stein; MAJ M. Switzer; MAJ M. Timlin; MAJ S. Wood

404 Naval Medical Center Portsmouth, Portsmouth, VA: G. Atwood: R. Carpenter; LCDR C. 405 Eickhoff; CAPT K. Kronmann; T. Lalani; LCDR T. Lee; T. Warkentien 406 Naval Medical Center San Diego, San Diego, CA: CAPT J. Arnold; CDR C. Berjohn; S. 407 Cammarata; LCDR S. Husain; LCDR A. Lane; CAPT R. Maves; J. Parrish; G. Utz 408 Tripler Army Medical Center. Honolulu, HI: S. Chi: MAJ E. Filan: K. Fong: CPT T. Horseman: 409 MAJ M. Jones; COL A. Kanis; LTC A. Kayatani; MAJ W. Londeree; LTC C. Madar; MAJ J. 410 Masel; MAJ M. McMahon; G. Murphy; COL V. Nguay; MAJ E. Schoenman; C. Uyehara; LTC R. 411 Villacorta Lyew 412 Uniformed Services University of the Health Sciences, Bethesda, MD: B. Agan; C. Broder; 413 CAPT T. Burgess; COL K. Chung; C. Coles; C. English; M. Haigney; COL P. Hickey; E. Laing; 414 LTC J. Livezey; A. Malloy; COL T. Oliver; E. Parmelee; S. Pollett; S. Richard; J. Rozman; M. 415 Sanchez; A. Scher; CDR M. Simons; A. Snow; D. Tribble 416 United States Air Force School of Medicine, Dayton, OH: A. Fries 417 Walter Reed National Military Medical Center, Bethesda, MD: A. Ganesan; D. Gunasekera; MAJ 418 N. Huprikar; M. Oyeneyin 419 William Beaumont Army Medical Center, El Paso, TX: CPT M. Banda; CPT B. Davis; MAJ T. 420 Hunter; CPT O. Ikpekpe-Magege; CPT S. Kemp; R. Mody; R. Resendez; COL M. Wiggins 421 Womack Army Medical Center, Fort Bragg, NC: B. Barton; D. Hostler; C. Maldonado 422 423 424 425

#### **REFERENCES**

426

- Widge AT, Rouphael NG, Jackson LA, et al. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *New England Journal of Medicine*, 2020;384(1):80-82.
- Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *medRxiv*. 2021:2021.2003.2017.20200246.
- 431 3. Ripperger TJ, Uhrlaub JL, Watanabe M, et al. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. *Immunity*. 2020;53(5):925-933.e924.
- 434 4. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. *Science*. 2020;370(6521):1227-1230.
- 5. Choe PG, Kim K-H, Kang CK, et al. Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection. *Emerging Infectious Disease journal*. 2021;27(3):928.
- 438 6. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nature Communications*. 2021;12(1):63.
- 7. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529):eabf4063.
- 442 8. Glück V, Grobecker S, Tydykov L, et al. SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19. *Infection*. 2021:1-8.
- Noh JY, Kwak JE, Yang JS, et al. Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19. *J Infect Dis.* 2021.
- Zheng Y, Zhang Q, Ali A, et al. Sustainability of SARS-CoV-2 Induced Humoral
   Immune Responses in COVID-19 Patients from Hospitalization to Convalescence Over
   Six Months. Virol Sin. 2021:1-10.
- Larson D, Brodniak SL, Voegtly LJ, et al. A Case of Early Reinfection With Severe
   Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical Infectious Diseases*. 2020.
- Torres DA, Ribeiro L, Riello A, Horovitz DDG, Pinto LFR, Croda J. Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: Case report. *J Med Virol*. 2021;93(4):1857-1859.
- Lee JS, Kim SY, Kim TS, et al. Evidence of Severe Acute Respiratory Syndrome
   Coronavirus 2 Reinfection After Recovery from Mild Coronavirus Disease 2019. *Clin Infect Dis.* 2020.
- 458 14. Alonso FOM, Sabino BD, Guimarães M, Varella RB. Recurrence of SARS-CoV-2 459 infection with a more severe case after mild COVID-19, reversion of RT-qPCR for 460 positive and late antibody response: Case report. *J Med Virol*. 2021;93(2):655-656.
- Kim AY, Gandhi RT. Re-infection with SARS-CoV-2: What Goes Around May Come
   Back Around. *Clin Infect Dis.* 2020.
- 463 16. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing Antibodies Correlate with 464 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High 465 Attack Rate. *Journal of Clinical Microbiology*. 2020;58(11):e02107-02120.
- Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS CoV-2 Infection in Health Care Workers. New England Journal of Medicine.
   2020;384(6):533-540.
- Schlickeiser S, Schwarz T, Steiner S, et al. Disease Severity, Fever, Age, and Sex
   Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Front Immunol*.
   2020;11:628971.

- Trinité B, Tarrés-Freixas F, Rodon J, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. *Sci Rep.* 2021;11(1):2608.
- 475 20. Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.

  477 *Nature Microbiology*. 2020;5(12):1598-1607.
- 478 21. Henss L, Scholz T, von Rhein C, et al. Analysis of Humoral Immune Responses in
   479 Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis.* 480 2021;223(1):56-61.
- 481 22. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody 482 responses in a COVID-19 convalescent plasma donor population. *J Clin Invest*. 483 2020;130(11):6141-6150.
- 484 23. Hansen CB, Jarlhelt I, Pérez-Alós L, et al. SARS-CoV-2 Antibody Responses Are
   485 Correlated to Disease Severity in COVID-19 Convalescent Individuals. *J Immunol*.
   486 2021;206(1):109-117.
- Wu J, Liang B, Chen C, et al. SARS-CoV-2 infection induces sustained humoral immune responses in convalescent patients following symptomatic COVID-19. *Nat Commun.* 2021;12(1):1813.
- 490 25. Röltgen K, Powell AE, Wirz OF, et al. Defining the features and duration of antibody 491 responses to SARS-CoV-2 infection associated with disease severity and outcome. 492 *Science Immunology*. 2020;5(54):eabe0240.
- 493 26. Hansen CH, Michlmayr D, Gubbels SM, Mølbak K, Ethelberg S. Assessment of
   494 protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals
   495 in Denmark in 2020: a population-level observational study. *Lancet*.
   496 2021;397(10280):1204-1212.
- 497 27. Yang HS, Costa V, Racine-Brzostek SE, et al. Association of Age With SARS-CoV-2 498 Antibody Response. *JAMA Netw Open.* 2021;4(3):e214302.
- 499 28. Antibody Response After SARS-CoV-2 Infection and Implications for Immunity. *Annals of Internal Medicine*.0(0):null.
- 501 29. Dugas M, Grote-Westrick T, Vollenberg R, et al. Less severe course of COVID-19 is 502 associated with elevated levels of antibodies against seasonal human coronaviruses OC43 503 and HKU1 (HCoV OC43, HCoV HKU1). *Int J Infect Dis.* 2021;105:304-306.
- 504 30. Anderson EM, Goodwin EC, Verma A, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell.* 2021.
- 506 31. Sermet-Gaudelus I, Temmam S, Huon C, et al. Prior infection by seasonal coronaviruses, 507 as assessed by serology, does not prevent SARS-CoV-2 infection and disease in children, 508 France, April to June 2020. *Euro Surveill*. 2021;26(13).
- 509 32. Guo L, Wang Y, Kang L, et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. *Emerg Microbes Infect*. 2021;10(1):664-676.
- 512 33. Khan S, Nakajima R, Jain A, et al. Analysis of Serologic Cross-Reactivity Between
   513 Common Human Coronaviruses and SARS-CoV-2 Using Coronavirus Antigen
   514 Microarray. *bioRxiv*. 2020.
- 515 34. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*. 2020;370(6522):1339-1343.

- 517 35. Selva KJ, van de Sandt CE, Lemke MM, et al. Systems serology detects functionally distinct coronavirus antibody features in children and elderly. *Nat Commun*. 2021;12(1):2037.
- Majdoubi A, Michalski C, O'Connell SE, et al. A majority of uninfected adults show preexisting antibody reactivity against SARS-CoV-2. *JCI Insight*. 2021.
- 522 37. Sagar M, Reifler K, Rossi M, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. *J Clin Invest*. 2021;131(1).
- 524 38. Laing ED, Sterling SL, Richard SA, et al. Antigen-based multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from seasonal human coronavirus humoral responses. *medRxiv*. 2021.
- 39. Lalani T, Lee TK, Laing ED, et al. SARS-CoV-2 Infections and Serologic Responses
   Among Military Personnel Deployed on the USNS COMFORT to New York City During
   the COVID-19 Pandemic. *Open Forum Infect Dis.* 2021;8(2):ofaa654.
- Clifton GT, Pati R, Krammer F, et al. SARS-CoV-2 Infection Risk Among Active Duty
   Military Members Deployed to a Field Hospital New York City, April 2020. MMWR
   Morb Mortal Wkly Rep. 2021;70(9):308-311.
- 533 41. Neerukonda SN, Vassell R, Herrup R, et al. Establishment of a well-characterized SARS-534 CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression 535 of ACE2 and TMPRSS2. *PLoS One*. 2021;16(3):e0248348.
- 536 42. Amanat F, White KM, Miorin L, et al. An In Vitro Microneutralization Assay for SARS-537 CoV-2 Serology and Drug Screening. *Curr Protoc Microbiol.* 2020;58(1):e108.
- 538 43. RStudio Team (2020). RStudio: Integrated Development for R. RStudio P, Boston, MA URL <a href="http://www.rstudio.com/">http://www.rstudio.com/</a>.
- 540 44. Sholukh AM, Fiore-Gartland A, Ford ES, et al. Evaluation of SARS-CoV-2 541 neutralization assays for antibody monitoring in natural infection and vaccine trials. 542 *medRxiv*. 2020:2020.2012.2007.20245431.
- Li K, Huang B, Wu M, et al. Dynamic changes in anti-SARS-CoV-2 antibodies during
   SARS-CoV-2 infection and recovery from COVID-19. *Nature Communications*.
   2020;11(1):6044.
- Ren L, Zhang L, Chang D, et al. The kinetics of humoral response and its relationship with the disease severity in COVID-19. *Communications Biology*. 2020;3(1):780.
- 548 47. Mor M, Werbner M, Alter J, et al. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors. *PLOS Pathogens*. 550 2021;17(2):e1009165.
- 48. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-Specific Adaptive
   Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease
   Severity. *Cell.* 2020;183(4):996-1012.e1019.
- 554 49. Pierce CA, Preston-Hurlburt P, Dai Y, et al. Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients. *Sci Transl Med.* 2020;12(564).
- 556 50. Sakharkar M, Rappazzo CG, Wieland-Alter WF, et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. *Sci Immunol.* 2021;6(56).
- 558 51. Ng KW, Faulkner N, Cornish GH, et al. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science*. 2020;370(6522):1339-1343.
- 560 52. Song G, He WT, Callaghan S, et al. Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *bioRxiv*. 2020.

53. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021. Crawford KHD, Dingens AS, Eguia R, et al. Dynamics of Neutralizing Antibody Titers 54. in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. The Journal of Infectious Diseases. 2020;223(2):197-205. 55. Wheatley AK, Juno JA, Wang JJ, et al. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nature Communications. 2021;12(1):1162. 56. Piccoli L, Park YJ, Tortorici MA, et al. Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell. 2020;183(4):1024-1042.e1021. 

# **TABLES**

# Table 1. Baseline characteristics of participants included in the longitudinal study of

# antibody responses.

	Outpatient (N=192)	Inpatient (N=58)
<b>Demographic Information</b>		
Age group		
<18	6 (3.1%)	0 (0.0%)
18-44	94 (49.0%)	9 (15.5%)
>44-64	78 (40.6%)	33 (56.9%)
≥65	14 (7.3%)	16 (27.6%)
Gender		
Female	86 (44.8%)	25 (43.1%)
Male	106 (55.2%)	33 (56.9%)
Race		
Black	27 (14.1%)	18 (31.0%)
Hispanic	60 (31.2%)	19 (32.8%)
Other	20 (10.4%)	4 (6.9%)
White	85 (44.3%)	17 (29.3%)
Days post-symptom onset at collection		
(n = 764)*	52 (0 - 385)	53 (1 - 378)

<sup>\*</sup>Median and range calculated based on days post-symptom onset at collection

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

FIGURE LEGENDS Figure 1. Evaluation of the magnitude and duration of the antibody response and COVID-19 clinical phenotype. Non-linear regressions were used to compare IgG responses from (A) outpatients (n=192) and inpatients (n=58). Longitudinal samples for subjects are connected by lines; second order polynomial curves were fit to inpatient (red) and outpatient (blue) groups; 95% CIs are shaded gray. A horizontal line indicates the indeterminate range between SARS-CoV-2 positive (>4774) and negative (<4144) IgG; MFI, median fluorescence intensity. Two distinct shaded regions highlighted early convalescence (vellow) and 6 months-post (pink) windows. (B) Early convalescence (median 35 dpso), six months-post (median 188 dpso) and twelve months-post (median 357 dpso) IgG responses were compared between outpatients and inpatients; error bars indicate the geometric mean and 95% CI. (C) Longitudinal SNT neutralizing antibody responses of outpatients (n=54) and inpatients (n=20). (D) Early convalescence and six months-post SNT neutralizing antibodies were compared by hospitalization status. P-values were determined by unpaired t-test with Welch's correction, α= 0.05; error bars indicate the geometric mean and 95% CI. Figure 2. The magnitude and durability of IgG-binding responses are associated with COVID-19 severity and age. (A) Multivariate linear regression analysis of outpatient and inpatient IgG responses and (B) hospitalization status stratified by age groups, outpatients, 18-44 (n=94), >44-64 (n=78), ≥65 (n=14), and inpatients, 18-44 (n=9), >44-64 (n=33), ≥65 (n=16) during early convalescence. A horizontal line indicates cutoff for positive/negative IgG; MFI, median fluorescence intensity. Statistical significance were determined by unpaired t-test with Welch's correction,  $\alpha = 0.05$ ; error bars indicate the geometric mean and 95% CI. (C-D) Six months-post IgG responses were compared between age-stratified outpatients and inpatients.

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

Figure 3. The magnitude and durability of neutralizing antibody responses are associated with COVID-19 severity and age. (A) Longitudinal SNT measurement of neutralizing antibodies in outpatient age groups, 18-44 (n=18), >44-64 (n=29) and ≥65 (n=6); longitudinal samples are connected by lines, second order polynomial curves and 95% CIs are shaded gray. (B) Early convalescence and six months-post SNT measured neutralizing antibodies compared between outpatient age groups. (C) Longitudinal SNT measurement of neutralizing antibodies in outpatient age groups, 18-44 (n=1), >44-64 (n=13) and ≥65 (n=6). (D) Early convalescence and six months-post SNT measured neutralizing antibodies compared between inpatient age groups. Statistical significance were determined by unpaired t-test with Welch's correction,  $\alpha =$ 0.05; error bars indicate the geometric mean and 95% CI. Figure 4. Seasonal HCoV antibody responses are not associated with COVID-19 clinical outcomes. (A) IgG binding levels of SARS-CoV-2 and seasonal HCoV-OC43, HCoV-HKU1, HCoV-229E, HCoV-NL63 detected in SARS-CoV-2 PCR-positive (n=505) and SARS-CoV-2 PCR-negative (n=92) samples. (B) Stratified SARS-CoV-2 positive samples (n=505) into age groups (18-44, >44-64, and ≥65 years old) and COVID-19 severity (outpatient vs. inpatient). MFI, median fluorescence intensity; dpso is from zero to twelve months; boxplots denote median, first quartile (25<sup>th</sup> percentile) and third quartile (75<sup>th</sup> percentile); statistical significance was determined by unpaired t-test with Welch's correction,  $\alpha = 0.05$ .







